SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 22nd, 2017 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 16, 2017, between XTL Biopharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES XTL BIOPHARMACEUTICALS LTD.Warrant Agreement • February 22nd, 2017 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after August ___, 2017 (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from XTL Biopharmaceuticals Ltd, an Israeli limited company (the “Company”), up to ______ Ordinary Shares (the “Warrant Shares”) represented by ________1 American Depositary Shares (“ADSs”), as subject to adjustment hereunder (the “Warrant ADSs”). The purchase price of one Warrant ADS shall be equal to the Exercise Price, as defined in Section 2(b).
STRICTLY CONFIDENTIAL XTL Biopharmaceuticals Ltd.Exclusive Agency Agreement • February 22nd, 2017 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
February 16, 2017 STRICTLY CONFIDENTIAL XTL Biopharmaceuticals Ltd.Engagement Agreement • February 22nd, 2017 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
